NAD+

Cellular energy, longevity pathway

Status

Available at launch

Mechanism

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to redox reactions in every cell. It is a required substrate for sirtuins (SIRT1–7) and PARPs, which regulate DNA repair, gene expression, and mitochondrial biogenesis. Parenteral NAD+ bypasses gut conversion inefficiency, delivering the coenzyme directly into circulation.

Indications

→Mitochondrial energy production

→Cognitive clarity and neuroprotection

→DNA repair support

→Metabolic function alongside GLP-1 weight-loss protocols

Regulatory status

NAD+ is available as an injectable via 503A compounding pharmacies. It is not FDA-approved as a drug but is recognized as a naturally occurring substance with established safety at therapeutic doses.

References

01Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules. Cell Metab. 2018.

02FDA 503A Bulk Drug Substances List — eligible.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.